BPI-7711 + rifampicin

**BPI-7711 + rifampicin** is a combination of **BPI-7711 (rezivertinib)**, a third-generation small molecule EGFR tyrosine kinase inhibitor (TKI), and **rifampicin**, an antibacterial agent and broad-spectrum antibiotic of the rifamycin class, typically used against mycobacterial infections including tuberculosis. - **BPI-7711 (rezivertinib)** is selectively active against EGFR-sensitizing mutations and the T790M resistance mutation in non-small cell lung cancer (NSCLC). It inhibits aberrantly activated EGFR signaling by binding to the kinase domain, blocking downstream oncogenic pathways, resulting in antiproliferative and pro-apoptotic effects[1][3][5]. - **Rifampicin** is a classic antibacterial drug that inhibits bacterial DNA-dependent RNA polymerase, blocking transcription of bacterial mRNA. Clinically, it is known as a potent inducer of CYP3A4 and CYP2C19 enzymes, which may substantially lower exposures to co-administered drugs metabolized by these enzymes, including TKIs like BPI-7711. - The combination may be examined to assess pharmacokinetic interactions or in clinical scenarios involving co-treatment, but rifampicin is not an anticancer agent; its inclusion would primarily affect the metabolism and pharmacokinetics of rezivertinib.

Brand names

Rezivertinib

Other names

BPI-7711BPI7711BPI 7711Rezivertinibrifampicin